TETERBORO, N.J., Feb. 23 /PRNewswire-FirstCall/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing,
information and services, announced that Joyce G. Schwartz, M.D., Vice
President and Chief Laboratory Officer, and Richard A. Bender, M.D., Medical
Director, Hematology/Oncology, are scheduled to speak at the Wachovia
Securities Cancer Diagnostics Conference on Tuesday, February 24, 2004, at The
New York Palace Hotel, in New York City. The Quest Diagnostics presentation is
scheduled to begin at 8:00 a.m. Eastern Time.
The presentation will be webcast live during the conference and will be
available to registered investors on the following site:
http://www.wallstreetwebcasting.com/webcast/fu19/dgx/ and to the public on
http://www.questdiagnostics.com. In addition, the archived webcast will be
available starting approximately three hours after the live presentation and
will be available for 60 days.
Quest Diagnostics Incorporated is the nation's leading provider of
diagnostic testing, information and services, providing insights that enable
physicians, hospitals, managed care organizations and other healthcare
professionals to make decisions to improve health. The company offers the
broadest access to diagnostic laboratory services through its national network
of laboratories and patient service centers. Quest Diagnostics is the leading
provider of esoteric testing, including gene-based medical testing, and
empowers healthcare organizations and clinicians with advanced information
technology solutions that improve practice management. Additional company
information can be found on the Internet at: http://www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results and
outcomes to be materially different. Certain of these risks and uncertainties
may include, but are not limited to, unanticipated expenditures, changing
relationships with customers, payers, suppliers and strategic partners,
competitive environment, changes in government regulations, conditions of the
economy, integration of acquired businesses, and other factors described in
the filings of Quest Diagnostics Incorporated with the Securities & Exchange
Commission, including its 2002 Form 10-K.
SOURCE Quest Diagnostics Incorporated
-0- 02/23/2004
/CONTACT: Investors: Laure Park, +1-201-393-5030, Media: Gary Samuels,
+1-201-393-5700/
/Web site: http://www.questdiagnostics.com /
(DGX)
CO: Quest Diagnostics Incorporated
ST: New Jersey